Breast cancer
Conditions
Interventions
singal-arm:pyrotinib
Sponsors
The Affiliated Hospital of Hebei Engineering University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 and 5cm; not receiving neoadjuvant treatment, postoperative pathological examination shows that there was lymph node metastasis. receiving neoadjuvant treatment, postoperative pathological examination shows there exists invasive cancer in breast and axillary lymph node. 5. Who have been accepted trastuzumab or combined with pertuzumab therapy. 6. Known about hormone receptor status ER/PR; 7. ECOG performence status 0-2 score.
Exclusion criteria
Exclusion criteria: 1. Subject who comfirmed local/regional recurrent/metastasis at the time of enrollment; 2. Subject who have previously received other TKI and T-DM1 treatment; 3. History of gastrointestinal disease,with diarrhea as the main symptom; 4. Subjects with a history of mental illness or psychotropic substance abuse, unable to cooperate; 5. Women who are pregnant or breastfeeding; 6. The investigators think its not suitable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Invasive disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Disease-free survival;Distance disease-free survival;Safety; | — |
Countries
China
Contacts
Public ContactHanJianJun
The Affiliated Hospital of Hebei Engineering University
Outcome results
None listed